- US Stock Market Movement | European bank stocks generally rise before the opening, Deutsche Bank (DB.US) up nearly 7%
- BUZZ - US new cloud concept stocks fall after Democrats' sweeping victory
- Adobe integrates enterprise collaboration tools with AI platforms from Anthropic, Google, Microsoft, and OpenAI.
- Clarivate launches cash tender offers for up to $500 million in notes
- Tyler Technologies Plans to Attend Five Investor Conferences
- Gilead and Kite Present Blood Cancer Therapy Data at ASH Annual Meeting
- Gilead to Present 18-Month Anito-cel Trial Follow-Up Data in Multiple Myeloma at ASH 2026
- RedCloud CEO to Attend 15th Annual ROTH Technology Conference
- Cullinan Therapeutics Reports Anti-Leukemic Activity in Phase 1 CLN-049 Study
- Immix Biopharma to Present NXC-201 Trial Data From 45 Patients at ASH 2026
- Rigel Announces Phase 1b R289 Data Presentation in Lower-Risk MDS at ASH
- Autolus data show leukemia responses deepen beyond first month after obe-cel treatment
- Siemens Healthineers publishes update to financial calendar
- Actinium Pharmaceuticals highlights Iomab-ACT clinical results in CAR T-cell therapy at ASH 2026
- Terreno Realty Signs 82,000-Square-Foot Lease in Avenel, New Jersey
- Agilent Completes Acquisition of Proscia
- Wall Street warns against excessive optimism: Post-midterm election stock market may not repeat historical gains
- HSBC raises its forecast for Saudi Aramco's crude oil production in Q4 2026 to 8.3 million barrels per day
- Stanley Black & Decker 3Q 2026 net earnings rise to $272.1 million
- Criteo Management Attributes Q3 2026 Contribution ex-TAC Decline to Lower Enterprise Spending, Retail Media Scope Reductions
- Datadog's 4Q Outlook Fails To Top Expectations, Largest Customer Reins in Usage -- Market Talk
- Par Pacific forecasts 2026 capital spending and turnaround costs of $190 million-$220 million
- Bitcoin's "Election Effect": Political Catalyst or Just Coinciding with the Halving Cycle?
- Aquestive Therapeutics forecasts 2026 revenue of $46 million-$50 million
- Penguin Solutions Reaffirms Fiscal 2027 Financial Outlook
- SoundHound AI Expands Ultraviolette Partnership to Power Electric Vehicle Voice Co-Pilot
- Daré Bioscience to Present at Stifel Healthcare Conference
- Penguin Solutions agrees to sell Cree LED to Transom Capital Group
- CVS Health outlines plan to split into two independent publicly traded companies
- Boron One Signs Three-Year Boron Supply Agreement With Singapore-Based Distributor
- Kura Oncology to Present First Ziftomenib-FLT3 Inhibitor Combination Trial Data at ASH 2026
- Lyell Immunopharma Announces $80 Million Private Placement
- BioMarin to Present at Stifel, UBS and Jefferies Investor Conferences
- BUZZ—WW Grainger stock rises as it raises its annual profit forecast and quarterly results beat market expectations
- Agilent Completes Acquisition Of Proscia >A
- Castor Maritime Subsidiary Agrees to Buy 41% Stake in Marlow Navigation for USD 126 Million
- Syndax Hosts Investor Event to Discuss ASH Data
- Update: 1-TeraWulf receives credit support from Google for Anthropic's data center project
- Lyell Immunopharma's Ronde-Cel Achieves 77% Complete Response Rate in Pivotal Lymphoma Trial
- Karyopharm reports sustained benefit through 48 weeks in Phase 3 selinexor myelofibrosis trial
- CRISPR Therapeutics Presents Zugo-cel Lymphoma Data at ASH Annual Meeting
- Sierra Bancorp Publishes Hovde Investor Conference Presentation
- Beam Therapeutics Reports Improved Patient-Reported Outcomes in Risto-cel Sickle Cell Trial
- SSR MINING INC. <SSRM.O>: UBS CUTS TARGET PRICE TO $37 FROM $39
- CSX CFO Kevin Boone to Address Baird Global Industrial Conference
- Gamehaus agrees to acquire 56% stake in Anamana parent Techforge
- 10-Yr Benchmark Govt Yields - Germany vs Other Nations
- 2-Yr Benchmark Govt Yields - Germany vs Other Nations
- 2-Yr Benchmark Govt Yields - U.S. vs Other Nations
- 10-Yr Benchmark Govt Yields - U.S. vs Other Nations
- Sellas Reports 57% Response Rate in TP53-Mutated AML With SLS009 Combination in Phase 2 Trial
- Geron says new analyses support RYTELO dosing in lower-risk myelodysplastic syndromes
- Top XRPL Validator Explains the Difference Between XRP and RLUSD
- Flowers Foods Elects Shaun Mara, Ken Plunk as Independent Directors
- Codere Online publishes update to financial calendar
- Legend Biotech's LB2501 Shows 100% Complete Response Rate in Eight Patients at Dose Level 2
- Invesco CFO Allison Dukes Participates in BMO Financials Conference Fireside Chat
- Lexaria Signs Agreement With Unnamed Pharmaceutical Company to Evaluate Drug Delivery Technology
- Incyte's INCA033989 shows spleen, symptom and anemia responses in Phase 1 myelofibrosis studies
- Amylyx Hosts Investor Event to Discuss Phase 3 Avexitide Results
- ADC Therapeutics’ Zynlonta-glofitamab combination shows 88.7% response rate in Phase 1b lymphoma trial
- CARRIER CONNECT DATA SOLUTIONS INC <CCDS.V>: CANACCORD GENUITY INITIATES COVERAGE WITH SPECULATIVE BUY RATING; PRICE TARGET C$3
- SSR MINING INC. <SSRM.TO>: UBS CUTS TARGET PRICE TO C$52 FROM C$55
- Ferrovial Raised to Buy From Neutral by Citigroup
- Natural Resource Partners Q3 Net Income, Revenue Drop
- Sector Update: Financial Stocks Edge Higher Pre-Bell Wednesday
- RBC Cuts Price Target on XPLR Infrastructure to $12 From $14, Keeps Outperform Rating
- Sector Update: Healthcare Stocks Advance Premarket Wednesday
- Exchange-Traded Funds, Equity Futures Rise Pre-Bell Wednesday as Investors React to US Midterm Election Results
- RBC Raises Price Target on Waters to $525 From $475, Keeps Outperform Rating
- MGE Energy Q3 Earnings, Revenue Rise
- Sector Update: Consumer Stocks Rise Pre-Bell Wednesday
- Navios Maritime Partners Q3 Adjusted Earnings, Revenue Increase
- Sector Update: Tech Stocks Mixed Pre-Bell Wednesday
- Array Technologies, Shoals to Merge in Stock-for-Stock Deal
- SolarEdge Technologies Q3 Swings to Adjusted Earnings, Revenue Falls; Q4 Outlook Issued
- Sector Update: Energy
- --UBS Adjusts Gartner Price Target to $220 From $208, Maintains Neutral Rating
- --UBS Adjusts Graphic Packaging Price Target to $11.50 From $9.50, Maintains Neutral Rating
- RBC Lifts Price Target on Pershing Square to $45 From $44, Keeps Sector Perform Rating
- Sector Update: Financial
- Shoals Technologies Q3 Adjusted Earnings, Revenue Rise; Raises 2026 Revenue Guidance
- Viridian Therapeutics Q3 Net Loss Widens, Revenue Drops
- Sector Update: Healthcare
- -- Earnings Flash (BRM.V) BIOREM Inc. Reports Q3 Revenue CA$16.6M, vs. FactSet Est of CA$13.3M
- Option Care Health's Q3 Adjusted Earnings, Revenue Rise; Withdraws Guidance Due to Pending Merger
- CVS Health 3Q Healthcare Benefits Segment Revenue Up 2.4% >CVS
- CVS Health 3Q Pharmacy & Consumer Wellness Segment Revenue $35.5B >CVS
- CVS Health Raises 2026 Cash Flow from Operations Guidance to at Least $15.5B from at Least $11.5B >CVS
- CVS Health 3Q Health Services Segment Revenue Up 9.5% >CVS
- CVS Health 3Q Pharmacy & Consumer Wellness Segment Revenue Down 2% >CVS
- CVS Health 3Q Adj. Operating Income $1.64B >CVS
- CVS Health: 3Q Adjusted EPS Rose Primarily Due to Improved Adjusted Operating Income in Health Care Benefits Segment >CVS
- CVS Health: 3Q Health Care Benefits Segment Rev Rose Primarily Driven by Increase in Govt Business, Partially Offset by Decline as Result of CO's Exit of Individual Exchange Business in 2026 >CVS
- CVS Health: 3Q Health Services Segment Rev Rose Primarily Driven by Pharmacy Drug Mix and Brand Inflation, Partially Offset by Continued Pharmacy Client Price Improvements >CVS
- CVS Health 3Q Same-Store Prescription Volume Rose 3.9% >CVS
- CVS Health 3Q Prescriptions Filled Rose 1.9% on 30-Day Equivalent Basis >CVS
- CVS Health Health Care Benefits Segment's 3Q Medical Benefit Ratio 91.3% >CVS
- CVS Health Raises 2026 EPS Guidance to at Least $6.98 from Prior View $6.84-$7.04 >CVS
- CVS Health Raises 2026 Adjusted EPS Guidance to at Least $8.20 from Prior View $7.90-$8.10 >CVS
